Table 1: Reimbursement recommendations by the CADTH Common Drug Review and listing decisions by 4 provincial drug plans for medicine-indication pairs.
| Health technology assessment agency or provincial payer | Reimbursement recommendation or listing decision; % of medicine-indication pairs (95% CI) | |
|---|---|---|
| Positive* | Negative* | |
| CADTH (n = 110) | 52.7 (43.5-61.8) | 47.3 (38.2-56.5) |
| Alberta Health (n = 95) | 58.9 (48.9-68.3) | 41.1 (31.7-51.1) |
| British Columbia Pharmacare (n = 106) | 54.7 (45.2-63.9) | 45.3 (36.1-54.8) |
| Ontario Drug Benefit Plan (n = 104) | 68.3 (58.8-76.4) | 31.7 (23.6-41.2) |
| INESSS (Quebec) (n = 102) | 69.6 (60.1-77.7) | 30.4 (22.3-39.9) |
Note: CI = confidence interval, INESSS = Institut national d'excellence en santé et en services sociaux.
*A recommendation/decision to reimburse the medicine, even if there were restrictions, was considered positive and a recommendation/decision to not reimburse was considered negative.